Publications and Patents

BOOK CHAPTERS

Beasley C, Grundy S, Gannon K, Berg P
Overview of the safety of olanzapine
In Tran P, Bymaster F, Tye N, Herrera J, Breier A, Tollefson G (Eds.)
Olanzapine (Zyprexa): A Novel Antipsychotic
Philadelphia: Lippincott Williams & Wilkins, 2000
Tran P. Sutton V, Beasley C, Tollefson G
Efficacy of olanzapine
In Tran P, Bymaster F, Tye N, Herrera J, Breier A, Tollefson G (Eds.)
Olanzapine (Zyprexa): A Novel Antipsychotic
Philadelphia: Lippincott Williams & Wilkins, 2000
Anderson J, Kline P, Beasley C
A general learning theory and its application to schema abstraction
In Bower G (Ed.)
The Psychology of Learning and Motivation, Vol 13.
New York: Academic Press, 1979
Anderson J, Kline P, Beasley C
Complex learning processes
In Snow R, Federico P & Montague W (Eds.)
Aptitude, Learning, and Instruction, Vol 2: Cognitive Process Analysis of Learning and Problem Solving
Hillsdale, NJ: Lawrence Erlbaum and Associates, 1980

ARTICLES

Beasley CM Jr, Crowe B, Nilsson M, Wu L, Tabbey R, Hietpas RT, Dean R, Horn PS

Adaptation of the robust method to large distributions of reference values: program modifications and comparison of alternative computational methods

J Biopharm Stat 29:516-528; 2019
Tumuklu MN, Tumuklu MM, Nesterenko V, Jayathilake K, Beasley CM Jr, Meltzer HY
24 hour measures of heart rate corrected QT interval (QTc), peak-to-end of the T-wave (Tpe), and Tpe/QTc ratio during antipsychotic treatment
J Clin Psychopharmacol 39:100-107; 2019
Beasley CM Jr, Crowe B, Nilsson M, Wu L, Tabbey R, Hietpas RT, Dean R, Horn PS
Reference limits for outlier analyses in randomized clinical trials
Ther Innov Regul Sci 6:668-737; 2017
Crowe B, Brueckner A, Beasley C, Kulkarni P
Current practices, challenges, and statistical issues with product safety labeling
Statistics in Biopharmaceutical Research 5:180-193; 2013
Loghin C, Haber H, Beasley CM, Kothare PA, Kauffman L, April J, jin L, Allen AJ, Mitchell MI
Effect of atomoxetine on the QT interval in healthy CYP2D6 poor metabolizers
Br J Clin Pharmacol 75:549-564; 2013
Beasley C, Benson C, Xia J, Young S, Haber H, Mitchell M, Loghin C
Systematic decrements in QTc between the first and second day of contiguous daily ECG recordings under controlled conditions
PACE 34:1116-1127; 2011
Millen BA, Campbell GM, Beasley CM
Weight changes over time in adults treated with oral or depot formulations of olanzapine: a pooled analysis of 86 clinical trials
J Psychopharmacol 25:639-645; 2011
Meyer RE, Salzman C, YoingstromEA, ClaytonPJ, Goodwin FK, Mann JJ, Alphs LD, Broich K, Goodman WK, Greden JF, Meltzer HY, Normand SL, Posner K, Shaffer D, Oquendo MA, Stanley B, Trivedi MH, Turecki G, Beasley CM, Beautrais AL, Bridge JA, Brown GK, Revicki DA, Ryan ND, Sheehan DV
Suicidality and risk of suicide – definition, drug safety concerns, and a necessary target for for drug development: a brief report
J Clin Psychiatry 71:1040-1046; 2010
Meyer RE, Salzman C, YoingstromEA, ClaytonPJ, Goodwin FK, Mann JJ, Alphs LD, Broich K, Goodman WK, Greden JF, Meltzer HY, Normand SL, Posner K, Shaffer D, Oquendo MA, Stanley B, Trivedi MH, Turecki G, Beasley CM, Beautrais AL, Bridge JA, Brown GK, Revicki DA, Ryan ND, Sheehan DV
Suicidality and risk of suicide – definition, drug safety concerns, and a necessary target for for drug development: a consensus statement
J Clin Psychiatry 71:pe1-pe21; 2010
Lipkovich I, Jacobson JG, Caldwell C, Hoffman VP, Kryzhanovskaya L, Beasley CM
Early predictors of weight gain risk during treatmentwith olanzapine: analysis of pooled data from 58 clinical trials
Psychopharm Bull 42:23-39; 2009
Beasley CM, Dmitrienko A, Mitchell MI
Design and analysis considerations for thorough QT studies employing conventional (10 s, 12-lead) ECG recordings
Expert Rev Clin Pharmacol 1:815-839; 2008
Beasley C, Ball S, Nilsson M, et al
Fluoxetine and adult suicidality revisited: an updated meta-analysis using expanded data sources from placebo-controlled trials
J Clin Psychopharmacol 27:682-686; 2007
Tauscher-Wisniewski S, Disch, Plewes J, Ball SG, Beasley CM
Evaluating suicidality as an adverse event in clinical trials of fluoxetine treatment for indications other than major depressive disorder
Psychol Med 37:1-9; 2007
Beasley CM, Stauffer VL, Liu-Seifert H, Taylor CC, Dunayevich E, Davis JM,
All-cause treatment discontinuation in schizophrenia during treatmrnt with olanzapine relative to other antipsychotics: an integrated analysis
J Clin Psychopharmacol 27:252-258; 2007
Perlis RH, Beasley CM, Wines JD, Tamura RN, Cusin C, Shear D, Amsterdam J, Quitkin F, Strong RE, Rosenbaum JF, Fava M
Treatment-associated suicidal ideation and adverse effects in an open, multicenter trial of fluoxetine for major depressive episodes
Psychother Psychosom 76:40-46; 2007
Cusin C, Fava M, Amsterdam JD, Quitkin FM, Reimherr FW, Beasley CM, Rosenbaum JF, Perlis RH
Early symptomatic worsening during treatment with fluoxetine in major depressive disorder: prevalence and implications
J Clin Psych 68:52-57; 2007
Crumb WJ, Ekins S, Darazan RD, Wikel JH, Wrighton SA, Carlson C, Beasley CM
Effects of Antipsychotic Drugs on I_to, I_Na, I_sus, I_K1, and hERG: QT prolongation, atructure activity relationship and network analysis
Pharmacol Res 23:1133-1143; 2006
Beasley CM, Sutton VK, Taylor CC, Sethuraman G, Dossenbach M, Naber D
Is quality of life among minimally symptomatic patients with schizophrenia better following withdrawal or continuation of antipsychotic treatment?
J Clin Psychopharmacol 26:40-44; 2006
Carrier S, Brock GB, Pommerville PJ, Shin J, Anglin G, Whitaker JS, Beasley CM
Efficacy and safety of oral tadalafil in the treatment of men in Canada with erectile dysfunction: a randomized, double-blind, parallel, placebo-controlled clinical trial
J Sexual Med 2:685-698; 2005
Beasley CM, Mitchell MI, Dmitrienko AA, Emmick JT, Shen W, Costigan TM, Bedding AW, Turick MA, Bakhtyari A, Warner MR, Ruskin JN, Cantilena LR, Kloner RA
The combined use of ibutilide as an active control with intensive ECG sampling and signal averaging as a sensitive method to assess the effects of taalafil on the human QT interval
J Am Coll Cardiol 46:678-687; 2005
Young JM, Feldman RA, Auerbach SM, Kaufman JM, Garcia CS, Shen W, Murphy AM, Beasley CM, Hague JA, Ahuja S
Tadalafil improved erectile function at 24 and 36 hours after dosing: US trial
J of Andrology 26:310-318; 2005
Sarazan RD, Crumb WJ, Beasley CM, Emmick JT, Ferguson KM, Strnat CA, Sausen PJ
Absence of clinically important HERG channel blockade by three compounds that inhibit phosphodiesterase 5 – sildenafil, tadalafil, and vardenafil
E J Pharmacology 502:163-167; 2004
Von Keitz A, Rajfer J, Segal S, Murphy A, Denne J, Costigan T, Lockhart D, Beasley C, Emmick J
A multicenter, randomized, double-blind, crossover study to evaluate patient preference between tadalafil and sildenafil
Eu Urology 45:499-507; 2004
Beasley C, Sutton V, Hamilton S, Walker D, Dossenbach M, Taylor C, Alaka K, Bykowski D, Tollefson G
A double-blind, randomized, placebo-controlled trial of olanzapine in the prevention of psychotic relapse
J Clin Psychopharmacol 23:582-594; 2003
Helstrom WJG, Overstreet JW, Yu A, Saikali K, Shen W, Beasley, CM, Watkins VS
Tadalafil has no detrimental effect on human spermatogenesis or reproductive hormones
J Urology 170:887-891; 2003
Carlson CD, Cavazzoni PA, Berg PH, Wei H, Beasley CM, Kane JM
An integrated analysis of acute treatment-emergent extrapyramidal syndrome in patients with schizophrenia during olanzapine clinical trials: comparisons with placebo, haloperidol, risperidone, or clozapine
J Clin Psychiatry 64:898-906; 2003
Lindborg S, Beasley C, Alaka K, Taylor C
Effects of intramuscular olanzapine vs. haloperidol and placebo on QTc intervals in acutely agitated patients
Psychiatry Res 119:113-123; 2003
Quitkin F, Petkova E, McGrath P, Taylor B, Beasley C, Stewart J, Amsterdam J, Fava M, Rosenbaum J, Reimherr F, Fawcett J, ChenY, Klein D
When should a trial of fluoxetine for major depression be declared failed?
Am J Psychiatry 160:734-740; 2003
Inada T, Beasley C, Tanaka Y, Walker D
Extrapyramidal symptom profiles assessed with DIEPSS: comparison with western scales in the clinical double-blind studies of schizophrenic patients treated with either olanzapine or haloperidol
Intl Clin Psychopharmacol 18:39-48; 2003
Sowell M, Mukhopadhyay N, Cavazzoni P, Shankar S, Steinberg H, Breier, Breier A, Beasley C, Dananberg J
Hyperglycemic clamp assessment of insulin secretory responses in normal subjects treated with olanzapine, risperidone, or olanzapine. J
Clin Endocrinology and Metab 87:2918-2923; 2002
Meehan K, Wang H, David S, Nisivoccia J, Jones B, Beasley C, Feldman P, Mintzer J, Beckett L, Breier A
Comparison of rapidly acting intramuscular olanzapine, lorazxepam, and placebo: a double-blind, randomized study in acutely agitated patients with dementia
Neuropsychopharmacology 26:494-504; 2002
Brunswick D, Amsterdeam J, Fawcett J, Quitkin F, Reimherr, Rosenbaum J, Beasley C
Fluoxetine and norfluoxetine plasma concentrations during relapse-prevention treatment
J Affect Diord 68:243-249; 2002
Kennedy J, Bymaster F, Schuh L, Calligaro D, Nomikos G, Felder C, Bernauer B, Kinon B, Baker R, Hau D, Roth H, Dossenbach M, Kaiser C, Beasley C, Holcombe J, Effron M, Breier A
A current review of olanzapine’s safety in the geriatric patient: from pre-clinical pharmacology to clinical data
Int J Geriatr Psychiatry 16:S33-S61; 2001
Brunswick D, Amsterdeam J, Fawcett J, Quitkin F, Reimherr, Rosenbaum J, Beasley C
Fluoxetine and norfluoxetine plasma levels after discontinuing fluoxetine therapy
J Clin Psychopharmacol 21:616-618; 2001
Czekalla J, Beasley C, Dellva M, Berg P, Grundy S
Analysis of the QTc interval during olanzapine treatment of patients with schizophrenia and related psychosis
J Clin Psychiatry 62:191-198; 2001
Czekalla J, Kollack-Walker S, Beasley C
Cardiac Safety Parameters of Olanzapine: comparison with other atypical and typical antipsychotics
J Clin Psychiatry 62:suppl 2:35-40; 2001
Czekalla J, Beasley CM, Ditmann RW, Helsberg K, Kollack-Walker S
Kardiale verträglichkeit unter nueroleptika: vergleichende übersicht zu Qtc-parametern und assoziierten effekten unter olanzapin und anderen atypischen sowie typischen antipsychotika
Nervenheilkunde 20:194-201; 2001
Perry P, Lund B, Sanger T, Beasley C
Olanzapine plasma concentrations and clinical response: acute phase results of the North American olanzapine trial
J Clin Psychopharmacol 21:14-20; 2001
Beasley C, Koke S, Nilsson M, Gonzales J
Adverse events and treatment discontinuations in clinical trials of fluoxetine in major depressive disorder: an updated meta-analysis
Clin Ther 22:1319-1330; 2000
Voss S, Sanger T, Beasley C
Hematologic reference ranges in a population of patients with schizophrenia
J Clin Psychopharmacol 20:653-657, 2000
Beasley C, Nilsson M, Koke S, Gonzales J
Efficacy, adverse events, and treatment discontinuations in fluoxetine clinical studies of major depression: a meta-analysis of the 20-mg/day dose
J Clin Psychiatry 61:722-728; 2000
McGrath P, Stewart J, Petkova E, Quitkin F, Amsterdam J, Fawcett J, Reimherr F, Rosenbaum J, Beasley C
Predictors of Relapse During Fluoxetine Continuation or Maintenance Treatment of Major Depression
J Clin Psychiatry 61:518-524; 2000
Michelson D, Amsterdam J, Quitkin F, Reimherr F, Rosenbaum J, Zajecka J, Sundell K, Kim Y, Beasley C
Changes in Weight During a 1-Year Trial of Fluoxetine
Am J Psychiatry 156:1170-1176; 1999
Revicki D, Genduso L, Hamilton S, Ganoczy D, Beasley C
Olanzapine versus haloperidol in the treatment of schizophrenia and other psychotic disorders: Quality of life and clinical outcomes of a randomized clinical trial
Qual Life Res 8:417-426; 1999
Amsterdam J, Garcia-Espana F, Fawcett J, Quitkin F, Reimherr F, Rosenbaum J, Beasley C
Fluoxetine efficacy in menopausal women with and without estrogen replacement
J Affect Disord 55:11-17; 1999
Callaghan J, Bergstrom R, Ptak L, Beasley C
Olanzapine: pharmacokinetic and pharmacodynamic profile
Clin Pharmacokinet 37:177-193; 1999
Amsterdam J, Garcia-Espana F, Fawcett J, Quitkin F, Reimherr F, Rosenbaum J, Beasley C
Blood pressure changes during short-term fluoxetine treatment
J Clin Psychopharmacol 19:9-14; 1999
Zajecka J, Amsterdam J, Quitkin F, Reimberr F, Rosenbaum J, Tamura R, Sundell K, Michelson D, Beasley C
Changes in adverse events reported by patients during 6 months of fluoxetine therapy
J Clin Psychiatry 60:389-394; 1999
Beasley C, Dellva M, Tamura R, Morgenstern H, Glazer W, Ferguson K, Tollefson G
Randomized double-blind comparison of the incidence of tardive dyskinesia in patients with schizophrenia during long-term treatment with olanzapine or haloperidol
Br J Psychiatry 174:23-30; 1999
Tran P, Tollefson G, Sanger T, Lu Y, Berg P, Beasley C
Olanzapine versus haloperidol in the treatment of schizoaffective disorder. Acute and long-term therapy
Br J Psychiatry 174:15-22; 1999
Sanger T, Lieberman J, Tohen M, Grundy S, Beasley C, Tollefson G
Olanzapine versus haloperidol treatment in first episode psychosis
Am J Psychiatry 156:79-87; 1999
Amsterdam J, Garcia-Espana F, Fawcett J, Quitkin F, Reimherr F, Rosenbaum J, Schweizer E, Beasley C
Efficacy and Safety of Fluoxetine in Treating Bipolar II Major Depressive Episode
J Clin Psychopharmacol 18:435-440; 1998
Reimherr F, Amsterdam J, Qutikin F, Rosenbaum J, Fava M, Zajecka J, Beasley C, Michelson D, Roback P, Sundell K
Optimal length of continuation therapy in depression: a prospective assessment during long-term fluoxetine treatment
Am J Psychiatry 155:1247-1253; 1998
Beasley C
Olanzapine: recent clinical findings and increased patient benefits
Japanese J Clin Psychopharmacol 1:759-765; 1998
Tollefson G, Sanger T, Beasley C, Tran P
A double-blind, controlled comparison of the novel antipsychotic olanzapine versus haloperidol or placebo on anxious and depressive symptoms accompanying schizophrenia
Biol Psychiatry 43:803-810; 1998
Tran P, Dellva M, Tollefson G, Wentley A, Beasley C
Oral olanzapine versus oral haloperidol in the maintenance treatment of schizophrenia and related psychoses
Br J Psychiatry 172:499-505; 1998
Zajecka J, Fawcett J, Amsterdam J, Quitkin F, Reimherr F, Rosenbaum J, Michelson D, Beasley C
Safety of abrupt discontinuation of fluoxetine: a randomized, placebo-controlled study
J Clin Psychopharmacol 18:193-197; 1998
Stewart J, Quitkin F, McGrath P, Amsterdam J, Fava M, Fawcett J, Reimherr F, Rosenbaum J, Beasley C, Roback P
Use of pattern analysis to predict differential relapse of remitted patients with major depression during 1 year of treatment with fluoxetine or placebo
Arch Gen Psychiatry 55:334-343; 1998
Hamilton S, Revicki D, Genduso L, Beasley C
Olanzapine versus placebo and haloperidol: quality of life and efficacy results of the North American double-blind Trial
Neuropsychopharmacology 18:41-49; 1998
Perry P, Sanger T, Beasley C
Olanzapine plasma concentrations and clinical response in acutely ill schizophrenic patients
J Clin Psychopharmacol 17:472-477; 1997
Dellva M, Tran P, Tollefson G, Wentley A, Beasley C
Standard olanzapine versus placebo and ineffective-dose olanzapine in the maintenance treatment of schizophrenia
Psychiatric Services 48:1571-1577; 1997
Goldstein D, Hamilton S, Masica D, Beasley C
Fluoxetine in Medically Stable, Depressed Geriatric Patients: Effects on Weight
J Clin Psychopharmacol 17:365-369; 1997
Crawford A, Beasley C, Tollefson G
The acute and long-term effect of olanzapine compared with placebo and haloperidol on serum prolactin concentrations
Schizophrenia Res 26:41-54; 1997
Tran P, Hamilton S, Kuntz A, Potvin J, Andersen S, Beasley C, Tollefson G
Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders
J Clin Psychopharmacol 17:407-418; 1997
Tollefson G, Beasley C, Tamura R, Tran P, Potvin J
Blind, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol
Am J Psychiatry 154:1248-1254; 1997
Beasley C, Tollefson G, Tran P
Safety of olanzapine
J Clin Psychiatry 58:Suppl 10:13-17; 1997
Beasley C, Tollefson G, Tran P
Efficacy of olanzapine: an overview of pivotal clinical trials
J Clin Psychiatry 58:Suppl 10:7-12; 1997
Blumenfield M, Levy N, Spinowitz B, Charytan C, Beasley C, Dubey A, Solomon R, Todd R, Goodman A, Bergstrom R
Fluoxetine in depressed patients on dialysis
Intl J Psychiatry in Medicine 27:71-80; 1997
Beasley C, Hamilton S, Crawford A, Dellva M, Tollefson G, Tran P, Blin O, Beuzen J
Olanzapine versus haloperidol: acute phase results of the international double-blind olanzapine trial
Euro Neuropsychopharmacol 7:125-137; 1997
Amsterdam J, Fawcett J, Quitkin F, Reimherr F, Rosenbaum J, Michelson D, Hornig-Rohan M, Beasley C
Fluoxetine and norfluoxetine plasma concentrations in major depression: a multicenter study
Am J Psychiatry 154:963-969; 1997
Tran P, Dellva M, Tollefson G, Beasley C, Potvin J, Kiesler G
Extrapyramidal Symptoms and tolerability of olanzapine versus haloperidol in the acute treatment of schizophrenia
J Clin Psychiatry 58:205-211; 1997
Tollefson G, Beasley C, Tran P, Street J, Kruger J, Tamura R, Graffeo K, Thieme M
Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial
Am J Psychiatry 154:457-465; 1997
Beasley C
Safety of olanzapine
J Clin Psychiatry Monograph 15:2:19-21; 1997
Beasley C
Efficacy of olanzapine
J Clin Psychiatry Monograph 15:2:17-19; 1997
Levy N, Blumenfield M, Beasley C, Dubey A, Solomon R, Todd R, Goodman A, Bergstrom R
Fluoxetine in depressed patients with renal failure and in depressed patients with normal kidney function
Gen Hosp Psychiatry 18:8-13; 1996
Beasley C, Sanger T, Satterlee W, Tollefson G, Tran P, Hamilton S
Olanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trial
Psychopharmacology 124:159-167; 1996
Beasley C, Tollefson G, Tran P, Satterlee W, Sanger T, Hamilton S
Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial
Neuropsychopharmacol 14:111-123; 1996
Tollefson G, Rampey A, Beasley C, Enas G, Potvin J
Absence of a relationship between adverse events and suicidality during pharmacotherapy for depression
J Clin Psychopharmacol 14:163-169; 1994
Tollefson G, Fawcett J, Winokur G, Beasley C, Potvin J, Faries D, Rampey A, Sayler M
Evaluation of suicidality during pharmacologic treatment of mood and non-mood disorders
Ann Clin Psychiatry 5:209-224; 1993
Beasley C, Holman S, Potvin J
Fluoxetine compared with imipramine in the treatment of inpatient depression : a multicenter trial
Ann Clin Psychiatry 5:199-207; 1993
Beasley C, Sayler M, Potvin J
Fluoxetine versus amitriptyline in the treatment of major depression: a multicenter trial
Intl Clin Psychopharmacol 8:143-149; 1993
Heiligenstein J, Beasley C, Potvin J
Fluoxetine not associated with increased aggression in controlled clinical trials
Intl Clin Psychopharmacol 8:277-280; 1993
Beasley C, Potvin J
Fluoxetine: activating and sedating effects
Intl Clin Psychopharmacol 8:271-275; 1993
Bergstrom R, Beasley C, Levy N, Blumenfield M, Lemberger L
A review of the effects of renal and hepatic disease on the pharmacokinetics, renal tolerance, and their risk-benefit profile of fluoxetine
Intl Clin Psychopharmacology 8:261-266; 1993
Beasley C, Masica D, Heiligenstein J, Wheadon D, Zerbe R
Possible monoamine oxidase inhibitor – serotonin uptake inhibitor interaction: fluoxetine clinical data and preclinical findings
J Clin Psychopharmacol 13:312-320; 1993
Goldstein D, Rampey A, Potvin J, Masica D, Beasley C
Analyses of suicidality in double-blind, placebo-controlled trials of pharmacotherapy for weight reduction
J Clin Psychiatry 54:309-316; 1993
Heiligenstien J, Coccaro E, Potvin J, Beasley C, Dornseif B, Masica D
Fluoxetine not associated with increased violence or aggression in controlled clinical trials
Ann Clin Psychiatry 4:285-295; 1992
Beasley C, Sayler M, Weiss A, Potvin J
Fluoxetine: activating and sedating effects at multiple fixed doses
J Clin Psychopharmacol 12:328-333; 1992
Wheadon D, Rampey A, Thompson V, Potvin J, Masica D, Beasley C
Lack of association between fluoxetine and suicidality in bulimia nervosa
J Clin Psychiatry 53:235-241; 1992
Beasley C, Dornseif B, Bosomworth J, Sayler M, Rampey A, Heiligenstein J, Thompson V, Murphy D, Masica D
Fluoxetine and suicide: a meta-analysis of controlled trials of treatment for depression
Intl Clin Psychopharmacol 6:Suppl 6:53-75; 1992
Beasley C, Masica D, Potvin J
Fluoxetine: a review of receptor and functional effects and their clinical implications
Psychopharmacology 107:1-10; 1992
Beasley C, Potvin J, Masica D, Wheadon D, Dornseif B, Genduso L
Fluoxetine: no association with suicidality in obsessive-compulsive disorder
J Affective Disorders 24:1-10; 1992
Beasley C, Dornseif B, Bosomworth J, Sayler M, Rampey A, Heiligenstien J, Thompson V, Murphy D, Masica D
Fluoxetine and suicide: a meta-analysis of controlled trials of treatment for depression
BMJ 303:685-692; 1991
Beasley C, Poltz J, Dornseif B, Bosomworth J, Sayler M
Fluoxetine versus trazodone: efficacy and activating-sedating effects
J Clin Psychiatry 52:294-99; 1991
Beasley C, Sayler M, Bosomworth J, Wernicke J
High-dose fluoxetine: efficacy and activating-sedating effects in agitated and retarded depression
J Clin Psychopharmacol 11:166-174; 1991
Usher R, Beasley C, Bosomworth J
Efficacy and safety of morning versus evening fluoxetine administration
J Clin Psychiatry 52:134-136; 1991
Beasley C, Sayler M, Cunningham G, Weiss A, Masica D
Fluoxetine in tricyclic refractory major depressive disorder
J Affective Disorders 20:193-200; 1990
Beasley C, Bosomworth J, Wernicke J
Fluoxetine: relationships among dose, response, adverse events, and plasma concentrations in the treatment of depression
Psychopharm Bull 26:18-24; 1990
McCombs J, Nichol M, Stimmel G, Sclar D, Beasley C, Gross L
The cost of antidepressant drug therapy failure: a study of antidepressant use patterns in a Medicaid population
J Clin Psychiatry 51:6, suppl:60-69; 1990
Beasley C, Magnusson M, Garver D
TSH response to TRH and haloperidol response latency in psychoses
Biol Psychiatry 24:423-31; 1988

LETTERS

Beasley C
Response (letter). Aust N Z J Psychiatry 33:12-122; 1999.

Perry PJ, Sanger T, Beasley CM
Plasma olanzapine and clinical response (Response letter). J Clin Psychopharmacol 19:193-194; 1999.

Beasley C
Response (letter). Br J Psychiatry 175:391-392; 1999.

Beasley C
Response (letter). CNS Drugs 9:513-515; 1998.

Beasley C
Response (letter). Neuropsychopharmacol 16:89-90; 1997.

Beasley C
Fluoxetine-Dopaminergic Interaction Data (letter). J Clin Psychiatry 55:77-78; 1994.

Masica D, Beasley C, Kotsanos J, Potvin J
Trend in suicide rates since fluoxetine introduction (letter). Am J Pub Health 82:1295; 1992.

Beasley C
Reply (letter). J Clin Psychopharmacol 12:220-221; 1992.

Beasley C
Fluoxetine and suicide (letter). BMJ 303:1200; 1991.

Fuller R, Beasley C
Fluoxetine: mechanism of action (letter). J Am Acad Child Adolesc Psychiatry 30:849-850; 1991.

Beasley C
Correction to ‘Fluoxetine Overdose: A Case Report’ (letter). J Anal Tox 14:63; 1990.

ABSTRACTS and POSTERS (selected)

Camporeale A, Beasley C, Tanaka Y, D’Souza D, Upadhyaya H
Changes in blood pressure and heart rate associated with atomoxetine treatment in attention-deficit/hyperactivity disorder
Euro Neuropsychopharmacol 22:429-430; 2012.
Gatz JL, Jamal HH, Plewes JM, Case MG, Beasley CM
Treatment-resistant major depressive disorder: comparison of acute (2-week) safety endpoints after switching treatment from other antidepressants to olanzapine/fluoxetine combination therapy
Annual Meeting of the American College of Neuropsychopharmacology. Holywood, FL, Dec. 7, 2009.
Beasley CM, Disch D, Chen W, Witte M, Acharya N, Perahia D, Nilsson, M, Perlis R
Potential risk factors for development of treatment-emergent suicidal ideation in the duloxetine placebo-controlled major depressive disorder database
Annual Meeting of the American College of Neuropsychopharmacology. Boca Raton, FL, Dec. 12, 2007.
Beasley CM, Disch D, Prabhakar V, Desiah D, Tamura R, Perlis R
Potential predictive factors for development of treatment-emergent suicidal ideation in the fluoxetine placebo-controlled major depressive disorder database
Neuropsychopharmacol 31:S1:100-101; 2006.
Acharya NV, Rosen AS, Polzer JP, DSouza DN, Perahia DG, Cavazzoni PA, Beasley CM, Baldessarini RJ
Duloxetine: meta-analysis of suicidal behaviors and thoughts in clinical trials for major depressive disorder
Neuropsychopharmacol 30:S1:S97; 2005.
Beasley CM, Sutton VK, Taylor C, Sethuraman G, Dossenbach M, Naber D, Pickar D
Does maintenance treatment with atypical antipsychotics worsen quality of life among stable patients with schizophrenia?
Neuropsychopharmacol 30:S1:S189; 2005.
Beasley C, Stauffer V, Liu-Seifert H, Rock S, Mitchell C, Dunayevich E, Davis J, Breier A
Overall treatment effectiveness as measured by time continuing on antipsychotic therapy
Neuropsychopharmacol 29:S1:S106; 2004.
Beasley C, Acharya N, Polzer J, Nilsson M, Rosen A, Cavazzoni P
Nomenclature for suicide-related thoughts and behaviors
American Academy of Child and Adolescent Psychiatry. Washington, DC, Oct. 21, 2004.
Beasley CM, Sowell MO, Carlson C, Mukhnopadhyay N, Dannanberg j, Henry R, Breier A, Cavazzoni P
Prospective evaluation of insulin sensitivity by the hyperinsulinemic, euglycemic clamp in healthy volunteers treated with olanzapine, risperidone or placebo
Schizophrenia Res 60:309, 2003.
Beasley C, Sowell M, Henry R, Carlson C, Mukhopadhyay N, Dananberg J, Cavazzoni P, Breier A
Prospective evaluation of insulin sensitivity by the hyperinsulinemic, euglycemic clamp in healthy volunteers treated with olanzapine, risperidone, or placebo
Annual Meeting of the American College of Neuropsychopharmacology. San Juan, PR, Dec. 11, 2002.
Czekalla J, Beasley C, David S, Berg P, Stauffer V, Boylan C
Cardiac conduction in females under intramuscular (IM) and oral olanzapine from schizophrenia clinical trials ECGs
Euro Neuropsychopharmacol 12:S3:S291-292; 2002.
Tohen M, David RS, Beasley CM, Alaka K
QT intervals: IM olanzapine treatment in acutely agitated patients
European Psychiatry 17:105; 2002.
Beasley C, Sowell M, Cavazzoni P, Breier A, Steinberg H, Dananberg J
Assessment of insulin secretory responses using the hyperglycemic clamp in normal subjects treated with olanzapine, risperidone, or placebo
Annual Meeting of the American College of Neuropsychopharmacology
Kona, HA, Dec. 10, 2001.
Beasley CM, Hamilton SH, Dossenbach M
Relapse prevention with olanzapine
Schizophrenia Res 41:196-197; 2000.
Czekalla J, Dellva MA, Berg PH, Grundy SL, Beasley CM
Cardiac safety profile of olanzapine based on preclinical and clinical ECG data
Schizophrenia Res 41:195; 2000.
Beasley C, Berg P, Dananberg J, Kwong K, Taylor C, Breier A
Incidence and rate of treatment-emergent potential impaired glucose tolerance and potential diabetes with olanzapine compared to other antipsychotic agents and placebo
Annual Meeting of the American College of Neuropsychopharmacology. San Juan, PR, Dec. 11, 2000.
Jones B, Wang H, David S, Nisivoccia J, Beasley C, Feldman P, Meehan K
A double-blind, placebo controlled study of short-acting intramuscular olanzapine and lorazepam in acutely agitated patients with dementia
Annual Meeting of the American College of Neuropsychopharmacology. San Juan, PR, Dec. 13, 2000.
Beasley CM, Hamilton SH, Dossenbach M
Relapse prevention with olanzapine
Euro Neuropsychopharmacol 10:304; 2000.
Crumb W, Beasley C, Thornton A, Breier A
Cardiac ion channel blocking profile of olanzapine and other antipsychotics
Annual Meeting of the American College of Neuropsychopharmacology. Alcapulco, Mexico, Dec. 13, 1999.
Tran PV, Basson BR, Kennedy JS, Beasley CM, Bymaster FP, Tollefson GD
The comparative anti-muscarinic-like side effect profiles of olanzapine and risperidone treatment in patients with schizophrenia spectrum psychosis
Euro Neuropsychopharmacol 9:290-291; 1999.
Schmidt M, Michelson D, Beasley CM, Kopp J, Koke S
Long term treatment outcomes of highly anxious depressed patients: evidence from a 52-week trial with fluoxetine
Euro Neuropsychopharmacol 9:209; 1999.
Basson B, Kennedy J, Tran P, Beasley C, Bymaster F, Tollefson G
The comparative anti-muscarinic-like side effect profiles of olanzapine and risperidone treatment in patients with schizophrenia spectrum psychosis
Annual meeting of the American College of Neuropsychopharmacology. Las Croabas, Puerto Rico, PR, Dec. 15, 1998.
Beuzen J, Birkett M, Kiesler G, Tollefson G, Wood A, Beasley C
Olanzapine vs
clozapine: an international double-blind study in treatment resistant schizophrenia
Annual meeting of the American College of Neuropsychopharmacology. Las Croabas, PR, Dec. 16, 1998.
Tamura R, Michelson D, Sundell K, Beasley C
Adverse event profiles associated with long-term fluoxetine treatment
American Psychiatric Association Annual Meeting. Toronto, Canada, June 3, 1998.
Beasley C, Tollefson G, Dellva M, Tamura R, Glazer W, Morgenstern H
The differential risk of tardive dyskinesia with olanzapine
American Psychiatric Association Annual Meeting. Toronto, Canada, June 2, 1998.
Wright P, Tollefson G, Beasley C, Tamura R, Tran P, Potvin J
A blinded, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol
Schizophrenia Res 29:206; 1998.
Jones B, Crawford A, Beasley C, Tollefson G
The acute and long-term effect of olanzapine compared with placebo and haloperidol on serum prolactin concentration
Schizophrenia Res 29:204-205; 1998.
Tamura R, Beasley C, Dellva M, Glazer W, Morgenstern H, Tollefson G
What is the differential risk of tardive dyskinesia with the novel antipsychotic olanzapine?
Schizophrenia Res 29:176; 1998.
Reams S, Sanger T, Beasley C
Olanzapine in the treatment of elderly patients with schizophrenia and related psychotic disorders
Schizophrenia Res 29:151-152, 1998.
Tran P, Lu Y, Sanger T, Beasley C, Tollefson G
Olanzapine in the treatment of schizoaffective disorder
Schizophrenia Res 29:151; 1998.
Beasley CM, Sayler ME, Kiesler GM, Potvin JH, Sanger TM, Tollefson GD
The influence of pharmacotherapy on self-directed and externally-directed aggression in schizophrenia
Schizophrenia Res 29:28; 1998.
Tollefson G, Sanger T, Beasley C
A blinded trial on the course and relationship of depressive symptoms in schizophrenia
Annual meeting of the American College of Neuropsychopharmacology. Kona, HA, Dec. 8, 1997.
Tran P, Tollefson G, Beasley C, Crawford A
From molecule to marketplace: profile of the atypical antipsychotic olanzapine
Annual meeting of the American College of Neuropsychopharmacology. Kona, HA, Dec. 10, 1997.
Beasley C, Tollefson G, Dellva M, Tamura R, Glazer W, Morgenstern H
What is the differential risk of tardive dyskinesia with the atypical antipsychotic olanzapine?
Annual meeting of the American College of Neuropsychopharmacology. Kona, HA, Dec. 10, 1997.
Dellva M, Tamura R, Glazer W, Morgenstern H, Beasley C
What is the differential risk of tardive dyskinesia with the atypical antipsychotic olanzapine?
Euro Neuropsychopharmacol 7:199-200; 1997.
Crawford A, Beasley C, Tollefson G
The acute and long-term effect of olanzapine compared with placebo and haloperidol on serum prolactin concentration
Euro Neuropsychopharmacol 7:199; 1997.
Crawford A, Gomez J, Beasley C, Tollefson G
Olanzapine versus haloperidol: analysis of schizophrenic patients from the multi-center international trial
Euro Neuropsychopharmacol 7:199; 1997.
Conley R, Tamminga C, Beasley C
Olanzapine vs. Chlorpromazine in treatment resistant schizophrenia
Annual meeting of the American College of Neuropsychopharmacology. San Juan, PR; Dec. 12, 1996.
Tran P, Dellva M, Rampey V, Tollefson G, Beasley C
Long-term continuation therapy with the novel antipsychotic olanzapine: a review of the clinical experience
Euro Neuropsychopharmacol 6:115; 1996.
Kuntz A, Tran P, Dellva M, Sanger T, Beasley C, Tollefson G
Acute phase efficacy and safety of olanzapine: a review
Euro Neuropsychopharmacol 6:115; 1996.
Dellva M, Satterlee W, Tran P, Beasley C, Greaney M, Tollefson G
Extrapyramidal symptoms and tolerability of olanzapine versus haloperidol in acute treatment
Euro Neuropsychopharmacol 6:106; 1996.
Lu Y, Sanger T, Beasley C, Tran P, Tollefson G
Olanzapine in the treatment of schizoaffective disorder
European Neuropsychopharmacology 6:106; 1996.
Tollefson G, Sanger T, Beasley C
The course of primary and secondary negative symptoms in a placebo- and comparator-controlled trial of the atypical antipsychotic olanzapine
Euro Neuropsychopharmacol 6:14; 1996.
Beasley C, Tran P, Satterlee W, Tollefson G, Lu Y, Kuntz A, Bradley P, Paul S
Olanzapine versus placebo, results of the United States double-blind olanzapine trial
Euro Neuropsychopharmacol 6:58; 1996.
Quicken FM, Stewart JW, McGrath PJ, Beasley C
Pattern analysis predicts relapse on fluoxetine and placebo during continuation
Euro Neuropsychopharmacol 6:153-154; 1996.
Tran P, Beasley C, Tollefson G, Dellva M, Hamilton S,Van Ostrand R, Paul S
Acute and long-term results of the North American double-blind olanzapine trial
Euro Neuropsychopharmacol 6:59; 1996
Martin C, Genduso L, Revicki D, Hamilton S, Tran P, Beasley C
Quality of life outcomes of olanzapine, a new atypical antipsychotic agent
Schizophrenia Res 18:130-131; 1996.
Tollefson GD, Beasley CM, Tran PV, Tamura RN, Sanger TM, Wood A, Beuzen JN
Olanzapine versus haloperidol: results of the multi-center international trial
Schizophrenia Res 18:131; 1996.
Tran P, Dellva M, Street J, Beasley C, Tollefson G, Kiesler G
Extrapyramidal symptoms and tolerability of olanzapine versus haloperidol in acute treatments
World Congress of Psychiatry. Madrid, Spain; Aug. 26, 1996.
Dellva M, Tran P, Beasley C, Cousins L, Krueger J, Tollefson G
Clinical experience with long-term continuation treatment with olanzapine
World Congress of Psychiatry. Madrid, Spain; Aug. 25, 1996.
Beasley C
Olanzapine safety overview
World Congress of Psychiatry. Madrid, Spain, Aug. 23, 1996.
Tollefson G, Sanger T, Beasley C
The course of primary and secondary negative symptoms in a controlled trial with olanzapine
CINP. Melbourne, Australia, June 26, 1996.
Tran P, Beasley C, Tollefson G, Dellva M, Hamilton S, Van Ostrand R, Paul S
Acute and long-term results of the North American double-blind olanzapine trial
CINP. Melbourne, Australia, June 25, 1996.
Tran P, Beasley C, Street J, Tamura R, Dellva M, Graffeo K, Kruger J, Tollefson G
Olanzapine versus haloperidol: acute results of the multi-center international trail
CINP. Melbourne, Australia, June 25, 1996.
Beasley C, Tran P, Beuzen J, Tamura R, Dellva M, Bailey J, Kruger J, Tollefson G
Olanzapine versus haloperidol: long-term results of the international trial
CINP. Melbourne, Australia, June 25, 1996.
Beasley C, Tran P, Satterlee W, Tollefson G, Lu Y, Kuntz A, Bradley P, Paul S
Olanzapine versus placebo, results of the United States double-blind olanzapine trial
CINP. Melbourne, Australia, June 25, 1996.
Tran P, Beasley C, Tollefson G, Satterlee W, Small J, Besancon G, Naber D, Sanger T, Bailey J, Wood A, Graffeo K, Meltzer H
Olanzapine in the treatment of schizophrenia and other psychotic disorders
NCDEU Annual Meeting. Boca Raton, FL, May 24, 1996.
Satterlee W, Beasley C, Sanger T, Tollefson G
a clinical update on olanzapine: atypical antipsychotic
NCDEU Annual Meeting. Boca Raton, FL, May 23, 1996.
Crawford A, Beasley C, Tollefson G
Olanzapine: impact of an atypical antipsychotic candidate on prolactin release
American Psychiatric Association Annual Meeting. New York, NY, May 9, 1996.
Patel B, Kurtz D, Callaghan J, Beasley C, Bergstrom R
Effect of smoking and gender on population pharmacokinetics of olanzapine
American Psychiatric Association Annual Meeting. New York, NY, May 8, 1996.
Tran P, Dellva M, Beasley C, Satterlee W, Cousins L, Tollefson G
Clinical experience with long-term continuation treatment with olanzapine
American Psychiatric Association Annual Meeting. New York, NY, May 8, 1996.
Satterlee W, Beasley C, Tran P, Tamura R, Krueger J, Tollefson G
Olanzapine versus haloperidol: results of a large multicenter international trial
American Psychiatric Association Annual Meeting. New York, NY, May 8, 1996.
Tollefson G, Sanger T, Beasley C
The course of primary and secondary negative symptoms in a controlled trial with olanzapine
American Psychiatric Association Annual Meeting. New York, NY, May 8, 1996.
Beasley C, Tollefson G, Tran P, Satterlee W, Sanger T
Olanzapine: molecule to drug candidate
American Psychiatric Association Annual Meeting. New York, NY, May 7, 1996.
Beasley C, Tran P, Tamura R, Tollefson G
Olanzapine versus haloperidol: results of the multi-center international trial
Annual Meeting of the American College of Neuropsychopharmacology. San Juan, PR, Dec. 15, 1995.
Tran P, Beasley C, Dellva M, Cousins L, Gusman S, Tollefson G
Long-term efficacy and safety of olanzapine
Annual Meeting of the American College of Neuropsychopharmacology. San Juan, PR Dec. 13, 1995.
Tran P, Beasley C, Crawford A, Hamilton S, Tollefson G
Acute and long-term results of the North American double-blind olanzapine trial
Belgian College of Neuropsychopharmacology and Biological Psychiatry (BCNBP). Kortenberg, Belgium, Dec. 1, 1995.
Tollefson G, Beasley C, Tran P, Sanger T
Olanzapine: an exciting atypical antipsychotic-the clinical experience
European College of Neuropsychopharmacology Annual Meeting. Venice, Italy, Oct. 1, 1995.
Dittmann R, Beasley C, Geuppert M, Muhlenbacher
Clinical efficacy and safety of olanzapine: results from a double blind-multinational trial
Pharmacopsychiatry 28:172; 1995.
Beuzen J, Tran P, Beasley C, Tollefson G, Sanger T, Hamilton S
Clinical efficacy and safety of increasing doses of olanzapine, a new “atypical” antipsychotic agent
CINP Regional Conference. Vienna, Austria and Prague, Czech Republic, June 10, 1995.
Beuzen J, Tran P, Beasley C, Tollefson G, Sanger T
Clinical efficacy and safety of olanzapine, a new “atypical” antipsychotic agent
CINP Regional Conference. Vienna, Austria and Prague, Czech Republic, June 10, 1995.
Beuzen J, Beasley C, Tran P, Sanger T, Paul S, Tollefson G
Additional clinical experience with olanzapine, an “atypical” antipsychotic
CINP Regional Conference. Vienna, Austria and Prague, Czech Republic, June 10, 1995.
Tran P, Beasley C, Tollefson G, Crawford A, Paul S
Olanzapine: an update on recent clinical studies
NCDEU Annual Meeting. Orlando, FL, June 1, 1995.
Tollefson G, Beasley C, Tran P, Satterlee W, Lu Y, Mesters P, Gomez J, Dittman R, Beuzen J, Graffeo K, Kolling C, Paul S
Olanzapine in the treatment of schizophrenia and other psychotic disorders
NCDEU Annual Meeting. Orlando, FL, May 31, 1995.
Tollefson G, Beasley C, Tran P, Sanger T
The next generation of antipsychotics
American Psychiatric Association Annual Meeting. Miami, FL, May 24, 1995.
Satterlee W, Beasley C, Sanger T, Tollefson G
Additional clinical experience with olanzapine, an atypical antipsychotic
American Psychiatric Association Annual Meeting. Miami, FL, May 24, 1995.
Tran P, Beasley C, Tollefson G, Blin O, Hamilton S, Wharton I, Cousins L, Kiesler G, Greaney M, Gussman S
Clinical efficacy and safety of increasing doses of olanzapine: a new “atypical” antipsychotic agent
American Psychiatric Association Annual Meeting. Miami, FL, May 23, 1995.
Tran P, Beasley C, Tollefson G, Satterlee W, Small J, Besancon G, Naber D, Sanger T, Bailey J, Graffeo K, Wood A, Meltzer H
Olanzapine in the treatment of schizophrenia and other psychotic disorders
American Psychiatric Association Annual Meeting. Miami, FL, May 23, 1995.
Beasley C, Tran P, Tollefson G, Satterlee W, Crawford A, Wharton I, Luttman C, Voegele T
Long-term efficacy and safety of olanzapine: a novel “atypical” antipsychotic agent
American Psychiatric Association Annual Meeting. Miami, FL, May 23, 1995.
Beasley C, Tollefson G, Tran P, Satterlee W
Olanzapine: a potential atypical antipsychotic
American Psychiatric Association Annual Meeting. Miami, FL, May 23, 1995.
Tran P, Beasley C, Tollefson G, Beuzen J, Holman S, Sanger T, Satterlee W
Olanzapine: a promising “atypical” antipsychotic agent
Schizophrenia Res 15:169; 1995.
Saterlee W, Beasley C, Sanger T, Tollefson G
Additional clinical experiences with olanzapine an “atypical” antipsychotic
Schizophrenia Res 15:163; 1995.
Satterlee W, Beasley C, Sanger T, Tran P, Paul S, Tollefson G
Olanzapine a new “atypical” antipsychotic
Schizophrenia Res 15:163-164; 1995.
Tollefson G, Sanger T, Beasley C, Tran P
Is there a relationship between EPSE and efficacy: fact or fiction
Scientific Council of the International Academy for Biomedical and Drug Research. Florence, Italy, Mar. 11, 1995.
Beuzen J, Beasley C, Satterlee W, Sanger T, Paul S, Tollefson G
Additional clinical experience with olanzapine, an “Atypical” Antipsychotic
Critical Issues in the Treatment of Schizophrenia Workshop. Florence, Italy, Mar. 11, 1995.
Tran PV, Beasley CM, Tollefson GD, Beuzen JN, Dellva MA, Sanger TM, Paul S
Acute and long-term results of the North American double-blind olanzapine trial
Euro Neuopsychopharmacol 5:347-348; 1995.
Amsterdam JD, Hornig-Rohan M, Rosenbaum JF, Quitkin FM, Fawcette J, Reimherr FW, Beasley CM
Fluoxetine and norfluoxetine levels in major depression
Biological Psychiatry 37:606; 1995.
Tollefson GD, Beasley CM, Tran PV, Sanger T
Olanzapine: a novel antipsychotic with broad spectrum profile
Biological Psychiatry 35:746-747; 1994.
Tran P, Beasley C, Satterlee W
Sanger T, Holman S, Tollefson G
Olanzapine: a potential novel antipsychotic agent
Annual Meeting of the American College of Neuropsychopharmacology. San Juan, PR, Dec. 14, 1994.
Tran P, Beasley C, Tollefson G, Beuzen J, Holman S, Sanger T, Satterlee W
Olanzapine: a promising “atypical” antipsychotic agent
Annual Meeting of the American College of Neuropsychopharmacology. San Juan, PR, Dec. 14, 1994.
Beasley C, Satterlee W, Sanger T, Paul S, Tollefson G
Additional clinical experiences with olanzapine an “atypical” antipsychotic
Annual Meeting of the American College of Neuropsychopharmacology. San Juan, PR, Dec. 14, 1994.
Satterlee W, Beasley C, Sanger T, Tran P, Paul S, Tollefson G
Olanzapine a new “atypical” antipsychotic
Annual Meeting of the American College of Neuropsychopharmacology. San Juan. Dec. 14, 1994.
Tran P, Beasley C, Tollefson G, Holman S
Clinical efficacy and safety of olanzapine: a novel antipsychotic agent
European College of Neuropsychopharmacology Annual Meeting. Jerusalem, Israel, Oct. 18, 1994.
Tran P, Beasley C, Tollefson G, Beuzen J, Holman S, Sanger T, Satterlee W
Olanzapine: a promising “atypical” antipsychotic agent
European College of Neuropsychopharmacology Annual Meeting. Jerusalem, Israel, Oct. 18, 1994.
Wood A, Beasley C, Tollefson G, Tran P
Efficacy of olanzapine in the positive and negative symptoms of schizophrenia
Euro Neuropsychopharmacol 4:224; 1994.
Tran P, Beasley C, Tollefson G, Beuzen J, Holman S, Sanger T
Olanzapine: a promising “atypical” antipsychotic agent
Plan Asian-Pacific Conference on Mental Health. Beijing, China, Oct. 12, 1994.
Tran P, Beasley C, Tollefson G, Satterlee W, Sanger T
Clinical efficacy and safety of olanzapine: a potential atypical antipsychotic agent
Pan Asian-Pacific Conference on Mental Health. Beijing, China, Oct 12, 1994.
Satterlee W, Beasley C, Sanger T, Tollefson G
A clinical update on olanzapine, an “atypical” antipsychotic
Institute on Hospital and Community Psychiatry Annual Meeting. San Diego, CA, Oct. 3, 1994.
Satterlee W, Beasley C, Tollefson G, Moore N, Tran P, Sanger T
Preclinical and clinical observations of olanzapine (a new antipsychotic agent)
Schizophrenia 1994: 3^rd International Conference. Vancouver, Canada, Aug. 23, 1994.
Tran P, Beasley C, Tollefson G, Sanger T, Satterlee W
Clinical efficacy and safety of olanzapine, a new atypical antipsychotic agent
Neuropsychopharmacol 10:3S, Part 2:267S; 1994.
Beasley C, Tollefson G, Moore N, Tye N
Olanzapine: the new “atypical” antipsychotic agent
Neuropsychopharmacol 10:3S, Part 1:536S; 1994.
Satterlee W, Beasley C, Tollefson G, Moore N, Tran P
Preclinical and clinical observations of olanzapine (a new antipsychotic)
NCDEU Annual Meeting. Marco Island, FL, June 2, 1994.
Rosenbaum J, Fava M, Quitkin F, Fawcett J, Amsterdam J, Reimherr F, Beasley C
Time to remission of depression with acute fluoxetine treatment
NCDEU Annual Meeting. Marco Island, FL, June 2, 1994.
Tran P, Beasley C, Tollefson G, Sanger T, Satterlee W
Clinical efficacy and safety of olanzapine, a new atypical antipsychotic agent
Canadian College of Neuropsychopharmacology Annual Meeting. Montreal, Canada, May 31, 1994.
Tran P, Beasley C, Tollefson G, Sanger T, Satterlee W
Clinical efficacy and safety of olanzapine: a new atypical Antipsychotic agent
American Psychiatric Association Annual Meeting. Philadelphia, PA, May 24, 1994.
Beasley C, Tollefson G, Tran P, Satterlee W
Olanzapine: a potential atypical antipsychotic
American Psychiatric Association Annual Meeting. Philadelphia, PA, May 24, 1994.
Beasley C, Tollefson G, Moore N
Olanzapine: a new “atypical” antipsychotic agent
Eighth Triannual Congress of the Israel Psychiatric Association. Tiberias, Israel, May 3, 1994.
Rosenbaum J, Quitkin F, Fava M, Amsterdam J, Fawcett J, Zajecka J, Lebegue B, Reimherr F, Beasley C
Fluoxetine vs. Placebo: long-term treatment of MDD
Annual Meeting of the American College of Neuropsychopharmacology. Honolulu, HA, Dec. 15, 1993.
Beasley C, Tollefson G, Tye N, Moore N
Olanzapine: a potential “atypical” antipsychotic agent
Annual Meeting of the American College of Neuropsychopharmacology. Honolulu, HA, Dec. 15, 1993.
Sayler M, Pande A, Beasley C, Tollefson G
Antidepressant efficacy and severity of depression
American Psychiatric Association Annual Meeting. San Francisco, CA, May 26, 1993.
Tye N, Moore N, Rees G, Sanger G, Calligaro D, Beasley C
Preclinical pharmacology of olanzapine: a novel ‘atypical’ antipsychotic agent
Second International Conference on Schizophrenia. Vancouver, Canada, July 21, 1992.
Beasley C, Montgomery S, Tye N
Olanzapine: an open-label study in schizophrenia
Second International Conference on Schizophrenia. Vancouver, Canada, July 21, 1992.
Beasley C, Sayler M
Fluoxetine: activating and sedating effects at multiple fixed doses
CINP. Nice, France, June 29, 1992.
Bergstrom R, Beasley C, Levy N, Dubey A, Blumenfield M, Goodman A, Solomon R
Fluoxetine pharmacokinetics after daily doses of 20 mg fluoxetine in patients with severely impaired renal function
Pharmaceutical Research 8:S294; 1991.
Heiligenstein J, Coccaro E, Potvin J, Beasley C, Dornseif B, Masica D
Fluoxetine not associated with violent behavior in controlled clinical trials
Clinical Research 39:768A; 1991.
Beasley C, Faries D, Sayler M, Potvin J
Fluoxetine not associated with suicidality in international controlled clinical trials in depression
Clinical Research 39:767A; 1991.
McDermott B, Beasley C, Kelly K, Hirschowitz J, Garver D
Confounds of neuroendocrine challenge tests
American Psychiatric Association Annual Meeting. Montreal, Canada, May 10, 1988.
Garver D, Beasley C, Kelly K, Magnusson M, Johnson C, Chopra Y
Antipsychotic response latencies: separate diseases
American Psychiatric Association Annual Meeting. Montreal, Canada, May 9, 1988.
Garver D, Beasley C, Sautter F, Chopra Y
Early antipsychotic response with neuroleptics and dopamine psychosis
Annual Meeting of the American College of Neuropsychopharmacology. San Juan, PR, Dec. 8, 1987.
Sautter F, McDermott B, Beasley C
Short-term outcome of schizophreniform disorder
American Psychiatric Association Annual Meeting. Chicago, IL, May 12, 1987.
Beasley C, Garver D
Growth hormone response and neuroleptic response in neuroleptic naïve patients
American Psychiatric Association Annual Meeting. Chicago, IL, May 12, 1987.
Beasley C, Magnusson M, Garver D
TSH response to TRH and haloperidol response latency in psychoses
Society for Biological Psychiatry Annual Meeting. Chicago, IL, May 7, 1987.

GRANT REPORTS

Anderson J, Kline P, Beasley C
A theory of the acquisition of cognitive skills
Technical Report 77-1. Yale University, 1978
Anderson J, Kline P, Beasley C
Complex learning processes
Technical Report 78-1. Yale University, 1978

PATENTS ISSUED

5605897       2-Methyl-Thieno-Benzodiazepine (Olanzapine)
5817656       Method for Treating Mental Disorders (Olanzapine)
5817657       Method for Treating Psychoactive Substance Disorders (Olanzapine)
5776928       Method for Treating Dyskinesia (Olanzapine)
6071902       Method for Treating Excessive Aggression (Olanzapine)
6159963       Method for Treating Substance Abuse (Olanzapine)
6274636       Method of Treating Tic Disorder (Olanzapine)
6506746       Method for Treating Cognitive Dysfunction (Olanzapine)